Boston-based Alexion Pharmaceuticals is set to acquire Achillion, a clinical-stage biopharma focused on the development of oral small molecule Factor D inhibitors to treat complement alternative pathway-mediated rare diseases. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, […]

Cambridge-based Ra Pharmaceuticals is being acquired by UCB, a global biopharma focused on diseases of the immune system or the central nervous system. Under the terms of the agreement, Ra Pharma shareholders will receive $48 in cash for each Ra Pharma share at closing. The Boards of Directors of both companies have unanimously approved the […]

Flagship Pioneering has unveiled Cambridge-based Cygnal Therapeutics which was founded in 2017 in Flagship Labs. Cygnal is the first company to develop drugs in the field of exoneural biology, a new understanding of how nerves and neural signaling drive human health and disease. The company has discovered biologically relevant pathways and advanced starting points for […]

Vertex Pharmaceuticals and RNA therapeutics developer Ribometrix, headquartered in Durham, North Carolina, have entered into a strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The collaboration will combine Ribometrix’s proprietary discovery platform for identifying and optimizing small molecule therapeutics that modulate RNA function by targeting three-dimensional (3D) RNA […]

Cambridge-based, clinical-stage biotech Moderna has announced a multi-year research collaboration with Harvard University to identify and develop novel therapeutic approaches that could improve the lives of patients with immunological diseases. Additional funding from Moderna to Harvard Medical School (HMS) will establish an initiative at HMS called the Alliance for RNA Therapies for the Modulation of […]